<p>NWF Advisory Services Inc. 在最近向证券交易委员会提交的文件中表示，在第二季度其在礼来公司的股份增加了 103.1%。该基金在季度内购买了额外的 1,002 股后，持有该公司 1,974 股股票。截至其最近的 SEC 文件，NWF Advisory Services Inc. 在礼来公司的持股价值为 1,539,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>黄金交叉提醒：3 只具有重大上涨潜力的股票</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也增加或减少了在 LLY 的持股。Lazard Freres Gestion S.A.S. 在第二季度将其在礼来公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S. 现在拥有 77,295 股该公司的股票，价值 60,253,000 美元，此前在上个季度购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的股份增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股该公司的股票，价值 229,000 美元，此前在上个季度购买了 39 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的股份增加了 6.8%。Capital Advisors Inc. OK 现在拥有 6,747 股该公司的股票，价值 5,260,000 美元，此前在上个季度购买了 429 股。Family CFO Inc 在第二季度收购了礼来公司的新股份，价值 54,000 美元。最后，Duquesne Family Office LLC 在第一季度将其在礼来公司的股份增加了 52.5%。Duquesne Family Office LLC 现在拥有 94,830 股该公司的股票，价值 78,321,000 美元，此前在上个季度购买了 32,640 股。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师最近对 LLY 股票发布了报告。Leerink Partners 将礼来公司的评级从 “市场表现” 上调至 “跑赢大盘”，并将其目标价格从 886.00 美元上调至 1,104.00 美元，报告发布于 11 月 10 日星期一。Erste Group Bank 在 10 月 14 日星期二将礼来公司的评级从 “持有” 上调至 “买入”。Guggenheim 在 12 月 3 日星期三重申了 “买入” 评级，并将礼来公司的目标价格设定为 1,163.00 美元。Berenberg Bank 在 12 月 2 日星期二将礼来公司的目标价格从 830.00 美元上调至 950.00 美元，并给予该公司 “持有” 评级。最后，Wall Street Zen 在 11 月 1 日星期六将礼来公司的评级从 “买入” 上调至 “强力买入”。三位投资分析师对该股票给予了强力买入评级，十六位分析师给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat 的数据，礼来公司目前的平均评级为 “适度买入”，平均目标价格为 1,121.90 美元。</p>
<ul>
<li>2026 年将主导的三大投资主题</li>
</ul>
<p><strong>查看我们最新的礼来公司股票报告</strong></p>
<h2>礼来公司的价格表现</h2>
<p>礼来公司的股票在周一开盘价为 1,027.68 美元。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,111.99 美元。该公司的债务与股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。该公司的 50 日移动平均价格为 939.47 美元，200 日移动平均价格为 820.35 美元。该公司的市值为 9715.5 亿美元，市盈率为 50.28，PEG 比率为 1.14，贝塔值为 0.37。</p>
<ul>
<li>5 个医疗保健领域值得关注的公司，因行业轮动正在全面展开</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日星期四公布了季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。该公司在本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司的季度收入较去年同期增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指引设定为 23.000-23.700 EPS。卖方分析师预测礼来公司今年将发布 23.48 美元的每股收益。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还披露了季度股息，将于 3 月 10 日星期二支付。2 月 13 日星期五的股东将获得 1.73 美元的股息。这是礼来公司之前季度股息 1.50 美元的积极变化。除息日期为 2 月 13 日星期五。这相当于年化股息 6.92 美元，股息收益率为 0.7%。礼来公司的股息支付比率（DPR）为 29.35%。</p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>投资于高市盈率成长股</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
<li>比较和交易高市盈率股票</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>股票市场行业：它们是什么，有多少个？</li>
<li>3 只金融股票在 10 年期国债收益率上升时值得购买</li>
</ul>
<p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eli Lilly and Company (NYSE:LLY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Eli Lilly and Company 吗？</h2>
<p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eli Lilly and Company 并不在名单上。</p>
<p>虽然 Eli Lilly and Company 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>NWF Advisory Services Inc. 在第二季度将其在礼来的股份增加了 103.1%，持有 1,974 股，价值 1,539,000 美元。其他投资者也调整了他们的持仓。分析师上调了礼来的股票评级，平均目标价为 1,121.90 美元。礼来报告第三季度每股收益为 7.02 美元，超出预期，营收同比增长 53.9%</p>

<p>NWF Advisory Services Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 103.1% during the second quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund owned 1,974 shares of the company's stock after buying an additional 1,002 shares during the quarter. NWF Advisory Services Inc.'s holdings in Eli Lilly and Company were worth $1,539,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>NWF Advisory Services Inc. 在最近向证券交易委员会提交的文件中表示，在第二季度其在礼来公司的股份增加了 103.1%。该基金在季度内购买了额外的 1,002 股后，持有该公司 1,974 股股票。截至其最近的 SEC 文件，NWF Advisory Services Inc. 在礼来公司的持股价值为 1,539,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉提醒：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Lazard Freres Gestion S.A.S. grew its position in shares of Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC lifted its stake in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares in the last quarter. Capital Advisors Inc. OK lifted its stake in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $54,000. Finally, Duquesne Family Office LLC increased its position in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after buying an additional 32,640 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也增加或减少了在 LLY 的持股。Lazard Freres Gestion S.A.S. 在第二季度将其在礼来公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S. 现在拥有 77,295 股该公司的股票，价值 60,253,000 美元，此前在上个季度购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的股份增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股该公司的股票，价值 229,000 美元，此前在上个季度购买了 39 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的股份增加了 6.8%。Capital Advisors Inc. OK 现在拥有 6,747 股该公司的股票，价值 5,260,000 美元，此前在上个季度购买了 429 股。Family CFO Inc 在第二季度收购了礼来公司的新股份，价值 54,000 美元。最后，Duquesne Family Office LLC 在第一季度将其在礼来公司的股份增加了 52.5%。Duquesne Family Office LLC 现在拥有 94,830 股该公司的股票，价值 78,321,000 美元，此前在上个季度购买了 32,640 股。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have recently issued reports on LLY shares. Leerink Partners upgraded Eli Lilly and Company from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and upped their price objective for the company from $886.00 to $1,104.00 in a research report on Monday, November 10th. Erste Group Bank upgraded shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, October 14th. Guggenheim reiterated a &#34;buy&#34; rating and set a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a &#34;hold&#34; rating in a research note on Tuesday, December 2nd. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $1,121.90.</p>
<div class="lb-trans"><p>几位分析师最近对 LLY 股票发布了报告。Leerink Partners 将礼来公司的评级从 “市场表现” 上调至 “跑赢大盘”，并将其目标价格从 886.00 美元上调至 1,104.00 美元，报告发布于 11 月 10 日星期一。Erste Group Bank 在 10 月 14 日星期二将礼来公司的评级从 “持有” 上调至 “买入”。Guggenheim 在 12 月 3 日星期三重申了 “买入” 评级，并将礼来公司的目标价格设定为 1,163.00 美元。Berenberg Bank 在 12 月 2 日星期二将礼来公司的目标价格从 830.00 美元上调至 950.00 美元，并给予该公司 “持有” 评级。最后，Wall Street Zen 在 11 月 1 日星期六将礼来公司的评级从 “买入” 上调至 “强力买入”。三位投资分析师对该股票给予了强力买入评级，十六位分析师给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat 的数据，礼来公司目前的平均评级为 “适度买入”，平均目标价格为 1,121.90 美元。</p>
</div><ul>
<li>The Top 3 Investment Themes That Will Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年将主导的三大投资主题</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的礼来公司股票报告</strong></p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>礼来公司的价格表现</h2>
</div><p>Eli Lilly and Company stock opened at $1,027.68 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The firm has a 50 day moving average price of $939.47 and a 200 day moving average price of $820.35. The company has a market cap of $971.55 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 1.14 and a beta of 0.37.</p>
<div class="lb-trans"><p>礼来公司的股票在周一开盘价为 1,027.68 美元。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,111.99 美元。该公司的债务与股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。该公司的 50 日移动平均价格为 939.47 美元，200 日移动平均价格为 820.35 美元。该公司的市值为 9715.5 亿美元，市盈率为 50.28，PEG 比率为 1.14，贝塔值为 0.37。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健领域值得关注的公司，因行业轮动正在全面展开</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business's quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日星期四公布了季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。该公司在本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司的季度收入较去年同期增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指引设定为 23.000-23.700 EPS。卖方分析师预测礼来公司今年将发布 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 3 月 10 日星期二支付。2 月 13 日星期五的股东将获得 1.73 美元的股息。这是礼来公司之前季度股息 1.50 美元的积极变化。除息日期为 2 月 13 日星期五。这相当于年化股息 6.92 美元，股息收益率为 0.7%。礼来公司的股息支付比率（DPR）为 29.35%。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Investing in the High PE Growth Stocks</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>投资于高市盈率成长股</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
<li>比较和交易高市盈率股票</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>股票市场行业：它们是什么，有多少个？</li>
<li>3 只金融股票在 10 年期国债收益率上升时值得购买</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eli Lilly and Company (NYSE:LLY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Eli Lilly and Company 吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eli Lilly and Company 并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eli Lilly and Company 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NWF Advisory Services Inc. 购买了礼来公司 $LLY 的股票